27
Sanofi has opened an insulin produc-
tion plant in Russia. How about
diabetes in general in Russia?
As discussed earlier in the interview,
yes we have a production plant in
Orel whose operations are focused
on meeting the needs of the Russian
patients in last generation insulins.
But when talking about fighting
diabetes in Russia, it is important to
mention that besides investments to
the development of the production
and export potential, Sanofi invests
into the large scale and research
projects, such as epidemiological
research studies. For example,
NATION, epidemiological study on
the prevalence of diabetes type 2 in
Russia.
The project was implemented in
cooperation with the Federal scientific
endocrinologic center in frames of
the MoU, which had been signed in
presence of the presidents of Russia
and France in 2013.
26 000 people, age 20 to 79 from
63 regions of the Russian Federation
participated in the study. Results
showed that there are 6 mln of
people with diabetes type 2 in Russia,
and 54% of the people with type 2
diabetes are not aware of their
diagnosis.
These results show that even though
we have moved quite far forward in
our fight against diabetes in Russia,
there is still a way to go.
What is your strategy in R&D?
At the heart of our R&D strategy are
the patients, and hence there is our
striving to provide the most advanced
and innovative treatment to as many
patients in Russia as possible.
Thus, our R&D strategy lays on 3
pillars: holding of our own clinical
studies, development of our portfolio
by the most advanced and innovative
molecules, and leveraging digital
solutions aimed at empowering
patients to better manage their
chronic conditions.
When talking about clinical studies,
it is important to say that clinical stu-
dies department has been operating
in Russian affiliate since 2004.
In cooperation with leading Russian
scientists multicenter research in
about 500 laboratories in Russia,
and with more than 5 thousand of
Russian patients taking part in
them. As for the last two pillars, we
have some interesting develop-
ments here, and I hope to be able to
tell you about them in a very close
future.
What is your contribution in term of
CSR?
For Sanofi responsibility and integrity
are the core principles of dialogue
and sustainable relations with its
stakeholders. Sanofi supports people
who meet challenges with their
health around the world.
In 2017, Sanofi held a photo exhibi-
tion “Overcoming” which introduces
to the public families of the people
with rare diseases.
What are your mid/long term project
in Russia?
To the above said, I would like to add
that Sanofi has been operating in
Russia for over 48 years, and we
remain committed to the country and
focused on investments and localiza-
tion since 2010 when we launched
production of Sanofi-Aventis Vostok
plant in Orel region. We believe that
our wide and diversified portfolio of
medicines covering various and most
demanded therapeutical areas, and
represented in different channels:
retail, tenders, and in the prevention
area contribute to delivering our key
strategic goal – improving access to
the most modern and innovative
medicines to as many patients in
Russia as possible.
>
Sanofi Russia teamat All-Russia ForumHealthy Nation - Prosperous Russia on April, 2017.
SANOFI
54 rue la Boétie - 75008 PARIS - France
©DR
Russia - France
